Orchard Therapeutics
101 Seaport Boulevard, 7th Floor
Boston
MA
02210
United States
Website: http://orchard-tx.com/
Email: careers@orchard-tx.com
About Orchard Therapeutics
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Orchard’s portfolio of ex vivo autologous gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first ex vivo autologous gene therapy approved by the EMA in 2016, three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD), transfusion-dependent beta-thalassemia (TDT) and mucopolysaccharidosis type I (MPS-I), as well as an extensive preclinical pipeline.
The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London and Boston.
101 articles with Orchard Therapeutics
-
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
10/16/2020
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants
-
BioSpace Global Roundup, Oct. 1
10/1/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
9/28/2020
Orchard Therapeutics, a global gene therapy leader, announced that the European Medicines Agency has granted Priority Medicines designation to OTL-203, an investigational ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.
-
Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences - Sep 09, 2020
9/9/2020
Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the following virtual investor conferences in September
-
BioSpace Global Roundup, Sept. 3
9/3/2020
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses. -
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
9/1/2020
Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorder Data support planned initiation of registrational trial in 2021 BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a
-
BioSpace Global Roundup, Aug. 27
8/27/2020
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines. -
Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
8/24/2020
Orchard Therapeutics, a global gene therapy leader, announced presentations at the upcoming 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, taking place virtually from August 29 - September 1, 2020.
-
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
8/6/2020
Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy ™ Expected in 2H 2020 MolMed and GSK Agreements Provide Near-term Manufacturing Capacity and Highlight Future Innovations Near-term Financial Position Secure with Cash and Investments of ~$230M and Runway into 2022 BOSTON and LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to
-
Orchard Therapeutics to Present at Wedbush PacGrow Healthcare Virtual Conference
8/4/2020
Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 AM ET.
-
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
7/30/2020
BOSTON and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 6, 2020, at 8:00 a.m. ET to review business updates and its second quarter 2020 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com . The conference call can be acce
-
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
7/20/2020
Orchard Therapeutics, a global gene therapy leader, announced that the company has received both orphan drug designation and rare pediatric disease designation from the U.S Food and Drug Administration for OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I.
-
Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK
7/15/2020
Orchard Therapeutics, a global gene therapy leader, announced that the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline plc for use of their proprietary lentiviral stable cell line technology for Orchard’s investigational hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia.
-
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
7/9/2020
Orchard Therapeutics, a global gene therapy leader, and MolMed S.p.A, one of the company’s principal contract development and manufacturing partners, announced that they have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Orchard Therapeutics to Present at Virtual Investor Conferences in June
5/27/2020
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made at the following investor conferences in June: Jefferies Virtual Global Healthcare Conference on June 3, 2020, at 9:00 AM ET Goldman Sachs Virtual Annual Global Healthcare Conference on June 11, 2020, at 11:20 AM ET Live webcasts of the presentations will be available under "News & Ev
-
Clinical Catch-Up: May 11-15
5/18/2020
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look. -
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
5/15/2020
Orchard Therapeutics, a global gene therapy leader, announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.
-
The culling of one-fourth of its employees is expected to save the company approximately $125 million through the end of 2021.
-
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
5/7/2020
Orchard Therapeutics, a global gene therapy leader, announced a new strategic plan to realize the potential of the hematopoietic stem cell gene therapy approach and reported its financial results for the quarter ended March 31, 2020.